Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Back up to half a penny on Friday. There may be no stopping this biotech juggernaut now, especially with all those new funds from the sale of Entest.
Koos and his note holder buddies will provide plenty of shares to keep that volume up I'm sure.
So you own GE too? LOL figures.
They are all shells the way they are set up. Koos could bail on any of them just like he did with Entest and leave investors holding the bag. You think you own a piece of the intellectual property? Not if it gets transferred to an entity that no shareholders own. Remember KCL, Therapeutics? What's it for? There's nothing stopping it from happening. I'm not saying it will happen but it could. That's why putting money in this crooked sham is just plain crazy.
Koos sold his controlling interest in ETNI for $325,000. That is not the kind of value that is going to make common shareholders in any of his companies any money.
And who benefits from that. So far just Koos.
They found millions of more shares since you posted that.
It's easy and meaningless to break volume records when the share price gets this low.
Usually when a company is bought the share price skyrockets. Here there's no action at all. LOL
Not sure what to make of it but the price was quite short of the billions that everybody projects here.
Bye bye Entest but there is something new called BST Partners. Whatever.
And now for a trip down memory lane... What ever came of this? I guess it helps to have a short memory if you want to invest in RGBP.
SAN DIEGO, California, August 25, 2016 /PRNewswire/ --
Regen BioPharma, Inc. (OTCQB: RGBP), (OTCQB: RGBPP), is pleased to announce that significant interest is being expressed by potential strategic partners with regards to the Company's proprietary assets. Previously, the Company had announced that partnering strategies were to be explored with the goal to provide sources of non-dilutive funding. Objective Capital Partners, LLC is serving as exclusive advisor to the Company and assisting in exploring strategic partnerships, co-development and licensing agreements to enhance shareholder value and provide sources of non-dilutive funding.
Yes, .005 per share is worth close to nothing.
Back below .005 today just as I predicted. I must have inside information or something.
If you read back they have been putting out this same PR periodically for over a year. Discovering a couple more compounds that have a reaction every couple of months have not moved this stock. If you can make a few bucks off this day trading then take the money and run. The long term trend is down down down.
That was a big share dump after news. Will be back below .005 by Thursday.
Here's your mega news that you've all been waiting for
PR Newswire
SAN DIEGO, November 13, 2018 /PRNewswire/ --
Regen BioPharma Inc. (RGRX) (OTCQB: RGBP) and (OTCQB: RGBPP) researchers have identified three new series of small molecule drugs that inhibit NR2F6, bringing the total number of these series to five.
"Finding potent small molecule inhibitors of NR2F6 is central to our goal of identifying and protecting the intellectual property landscape around this program. Therefore, we continue to screen for NR2F6 inhibitors using a second proprietary assay and have identified three new series of drugs that inhibit NR2F6 in a concentration-dependent manner," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen.
"As we move some of these molecules forward in our development program, we will submit the appropriate patent filings to continue to add value to the program and Regen shareholders," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc.
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 small molecule program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
http://www.regenbiopharma.com
david.koos@regenbiopharma.com
Mega Ho Hum same old same old looks like the last six PRs.
And Zander is getting RGBP convertible notes for those funds. Soon Regen will be a subsidiary of Zander not to mention it's very ponzu like.
All the focus is now on Zander. Regen is just here to pay for the research for Zander. Don't be fooled into thinking that Regen will benefit. Zander becomes less amd less of a subsidiary of Regen every month.
Maybe the fat man in La Mesa is rocking an Ihub handle so he can help his buddies unload their convertible shares.
New all time MEGA low was hit today.
With a seemingly never ending supply of shares being sold every day that is very true. There's not enough buyers to take them out. These base builders need to call in their friends to help.
Nope. This stock is trash.
Share price has to go up more than 50% to get back to a penny.
Maybe tomorrow will be MEGA!
"As time goes on, of course, Zander will issue and sell more shares, increasing Zander's Market Cap."
Then they should just issue and sell 500 billion shares and have a trillion dollar market cap. They'll be as big as Amazon!
It doesn't work that way. Issuing and selling more shares is called dilution. Go see what it has done for BMSN and RGBP.
I know, I know. You'll now tell me that ETNI/Zander are different. They're not.
The only thing that will stop it is a reverse split.
Another MEGA close.
Some time ago Koos hired a firm to shop around for a deal for this old IP that is sitting around collecting dust to help fund research on Nerf molecule. Nothing ever came of it so I would assume that there is nothing of value.
He is genius in the way that he is having RGBP carry the cost for Zanders research. He's setting up these shareholders to be bagholders.
Looks like no MEGA is happening today.
Buyers of this stock are not concerned with making a profit. They are funding important research. That research was supposed to cure cancer and autoimmune diseases but now the bar has been lowered to curing animal IDB. Basically Koos wants to conquer the highly profitable drug marketplace of helping dogs to have comfortable bowel movements.
RGBP did not end lower today. That's mega.
It's like Linus waiting for the Great Pumpkin.
But it dilutes RGBP to prop up the value of Entest and Zander. It's going to make Regen stock worthless eventually if they keep doing that.
I cannot consider moving money from Entest to Regen an investment. They are intertwined and basically all one entity when it comes down to business. The shift of $300,000 just makes the appearance of this being a ponzu scheme more apparent.
Exactly correct. The problem is there is no foreseeable end to conviction because new notes are being issued every month. We will see how much worse it has gotten with the next 10q. All of these shares are not just being made up by the MMs or baked short traders in spite of what the excuse makers want to believe. Simply put,it's dilution.
A little market education for the people living in fantasy land here. The short positions in RGBP are being taken by market makers to facilitate trades in this thinly traded stock. They are not trying to manipulate the stock. They are just trying to make their trading fees off of the volume of daily trading. There are probably no retail traders shorting this stock simply because their brokers would not authorize it. I am not shorting this stock. I trade with an account with Ally Bank and they would certainly not authorize me to short a thinly traded OTC stock like RGBP. The only people that would or could are people with huge margins (and why would they bother?) and the previously mentioned market makers that are just facilitating trades. Does this make sense to any of you?
I guess that by that train of thought then every stock with an active message board must be ready to boom.
I would recommend waiting until it hits .008